Safety and Tolerability Evaluation of MaaT033

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-10-20

Study Completion Date

2021-12-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Richness and diversity of gut microbiota are increasingly found to be associated with cancer outcomes. Moreover, an adequately responsive immune system seems to rely on the existence of a functioning gut ecosystem that includes the microbiota and its natural environment.

Cancer by itself, but also cancer treatments - in particular chemotherapy - induce gut dysbiosis, impair the constant reparation mechanisms of the gut epithelium, disrupt immune homeostasis, and stunt immune responsiveness.

The objective of MaaT033 is to (1) prevent the decay of the gut ecosystem (dysbiosis) to preserve immune homeostasis, (2) restore and optimize the gut ecosystem to full functionality including its role in repairing the gut epithelium and healthy gut barrier, and (3) maintain a restored gut ecosystem and fully functional immune homeostasis.

Restoring the full gut ecosystem and its associated microbiota could become an important therapeutic option to improve clinical outcomes and control adverse events of conventional approaches, including immunotherapy in cancer patients.

As a first step, MaaT033 capsules containing lyophilized, pooled, full-ecosystem microbiota in its natural environment are to be tested for their safety and tolerability in hematological malignant patients, who are exposed to intensive rounds of chemotherapy and antibiotics.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors

NCT05037825

Non-Small-Cell Lung Carcinoma Malignant Melanoma Renal Cell Carcinoma +1 more

RECRUITING

Masitinib in Patients With Gastro-Intestinal Stromal Tumour Resistant to Imatinib

NCT01506336

Gastro Intestinal Stromal Tumor

COMPLETED PHASE2

Endogenous Mechanisms of Inactivation of the Endothelium Tumor

NCT03667612

Breast Cancer Colon Cancer

UNKNOWN

Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients

NCT04038619

Colitis Diarrhea Malignant Genitourinary System Neoplasm +6 more

RECRUITING PHASE1

Study of Labetuzumab Govitecan in Participants With Metastatic Colorectal Cancer

NCT01605318

Metastatic Colorectal Cancer Colon Cancer Rectal Cancer

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hematologic Diseases Chemotherapy Effect

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SEQUENTIAL

3+3 design dose escalation

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

MaaT033 treatment

A Lyophilized Full-ecosystem Gut Microbiota Delayed-release Capsule

Group Type EXPERIMENTAL

MaaT033 capsule

Intervention Type DRUG

Oral capsule

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

MaaT033 capsule

Oral capsule

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or Female
2. Age ≥ 18 years
3. Patients diagnosed with AML defined according to WHO 2016 criteria with ≥20% leukemic blasts in the bone marrow or with high- risk myelodysplastic syndrome, receiving intensive chemotherapy
4. Patients healthy enough to likely receive their consolidation or second cycle of chemotherapy after induction chemotherapy
5. Patients healthy enough to likely receive HSCT
6. Informed written consent
7. Patient recovered from neutropenia

Exclusion Criteria

1. Acute promyelocytic leukemia (AML-M3)
2. AML secondary to myeloproliferative disorder or chronic myelomonocytic leukemia (CMML)
3. Acute myeloid leukemia BCR-ABL1+
4. Active CNS leukemia
5. Patients with a life expectancy of \<70 days according to investigator's opinion, or subject to therapeutic limitations
6. Confirmed or suspected intestinal ischemia
7. Confirmed or suspected toxic megacolon or gastrointestinal perforation
8. Active uncontrolled infection according to the attending physician
9. Any gastro-intestinal bleeding in the past 3 months
10. Any history of gastro-intestinal surgery in the past 3 months
11. Any history of inflammatory bowel disease
12. Any counter-indication to swallow capsules
13. Enrollment in another trial that may interfere with this study
14. Known allergy or intolerance to trehalose, maltodextrin or PEG
15. Women of childbearing potential without efficient contraceptive protection
16. Pregnant or breastfeeding
17. Patients with EBV-negative serology
18. Subject who, in the judgment of the Investigator, is likely to be non-compliant or uncooperative during the study, or unable to cooperate because of a language problem, poor mental development;
19. Exclusion period of a previous study
20. Administrative or legal supervision
21. Confirmed positive result to SARS-CoV-2 nasopharyngeal test at screening

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No